Research Analysts Issue Forecasts for DAWN Q1 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Equities researchers at HC Wainwright lowered their Q1 2025 earnings estimates for Day One Biopharmaceuticals in a report issued on Thursday, April 3rd. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.37) for the quarter, down from their prior forecast of ($0.28). HC Wainwright currently has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.75 EPS, FY2028 earnings at $0.84 EPS and FY2029 earnings at $1.35 EPS.

DAWN has been the subject of a number of other reports. Wedbush reissued an “outperform” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. JPMorgan Chase & Co. reduced their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, Bank of America cut their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $32.29.

Day One Biopharmaceuticals Stock Down 6.4 %

Shares of DAWN stock opened at $7.22 on Monday. The stock has a 50-day simple moving average of $10.13 and a 200 day simple moving average of $12.38. The stock has a market capitalization of $731.78 million, a P/E ratio of -7.01 and a beta of -1.24. Day One Biopharmaceuticals has a fifty-two week low of $7.06 and a fifty-two week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million.

Insider Activity

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at $1,531,059.40. The trade was a 8.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the sale, the chief financial officer now owns 252,638 shares of the company’s stock, valued at $3,021,550.48. The trade was a 1.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,064 shares of company stock worth $251,925 over the last 90 days. 8.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors have recently bought and sold shares of the business. FMR LLC lifted its position in shares of Day One Biopharmaceuticals by 73.9% in the fourth quarter. FMR LLC now owns 12,887,467 shares of the company’s stock worth $163,284,000 after purchasing an additional 5,475,087 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Day One Biopharmaceuticals in the 4th quarter valued at approximately $31,829,000. Boxer Capital Management LLC purchased a new stake in Day One Biopharmaceuticals in the 4th quarter worth approximately $15,077,000. Marshall Wace LLP acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at $13,909,000. Finally, Estuary Capital Management LP boosted its stake in shares of Day One Biopharmaceuticals by 35.5% during the 4th quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company’s stock valued at $47,092,000 after buying an additional 972,997 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.